Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA

Ushigome, Mitsunori; Shimada, Hideaki; Miura, Yasuyuki; Yoshida, Kimihiko; Kaneko, Tetsuya; Koda, Takamaru; Nagashima, Y.; Suzuki, Takayuki; Kagami, Satoru; Funahashi, Kimihiko

doi:10.1007/s10147-019-01597-6

Cited by 28 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p53 has also been found to be an autoantigen in colorectal cancer and, in a metaanalysis considering 199 antigens, it was found to be an important auto-antibody for diagnostic purposes in combination with those against c-MYC, cyclin B1, p62, Koc, IMP1, and survivin [42]. Even alone, p53 auto-antibodies were able to predict the likelihood to develop colorectal cancer within 6 years [43], although their presence at recurrence was not found to be a relevant prognostic factor [44]. Disease-free individuals and carriers of metastatic colorectal cancer could be distinguished using ERP44 and TALDO1 antigens [45].…”

Section: Colorectal Cancermentioning

confidence: 99%

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Jonge

Iamele

Maggi

et al. 2021

Cancers

View full text Add to dashboard Cite

Auto-antibodies are classically associated with autoimmune diseases, where they are an integral part of diagnostic panels. However, recent evidence is accumulating on the presence of auto-antibodies against single or selected panels of auto-antigens in many types of cancer. Auto-antibodies might initially represent an epiphenomenon derived from the inflammatory environment induced by the tumor. However, their effect on tumor evolution can be crucial, as is discussed in this paper. It has been demonstrated that some of these auto-antibodies can be used for early detection and cancer staging, as well as for monitoring of cancer regression during treatment and follow up. Interestingly, certain auto-antibodies were found to promote cancer progression and metastasis, while others contribute to the body’s defense against it. Moreover, auto-antibodies are of a polyclonal nature, which means that often several antibodies are involved in the response to a single tumor antigen. Dissection of these antibody specificities is now possible, allowing their identification at the genetic, structural, and epitope levels. In this review, we report the evidence available on the presence of auto-antibodies in the main cancer types and discuss some of the open issues that still need to be addressed by the research community.

show abstract

Section: Colorectal Cancermentioning

confidence: 99%

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Jonge

Iamele

Maggi

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 68%

“…Other cancer types demonstrated similar positive rates of around 6 to 7%. Although the overall positive rate of s-GAL-1-Abs was not higher than that of conventional tumor markers (13,(18)(19)(20)(21), it was found to be positive in various cancer types. The differences of the positive rates of s-GAL-1-Abs among various cancer types might be associated with the positive rates of galectin-1 protein expression in the tumor tissues.…”

Section: Resultsmentioning

confidence: 72%

Prevalence of serum galectin‑1 autoantibodies in seven types of cancer: A potential biomarker

et al. 2021

Self Cite

View full text Add to dashboard Cite

Although serum galectin-1 antibodies (s-GAL-1-Abs) have been evaluated in a small number of patients with cancer, a large series of patients with different cancer types have not been reported. The current study evaluated 1,833 patients with esophageal cancer (n=172), gastric cancer (n=317), colorectal cancer (n=262), hepatocellular carcinoma (n=91), prostate cancer (n=358), breast cancer (n=364), lung cancer (n=269) and 72 healthy individuals. s-GAL-1-Abs levels were analyzed using an originally developed ELISA system. A cut-off optical density value was determined as the mean (0.053) + 3 standard deviations (0.105) of sera from healthy controls. The results revealed that the positive rate of s-GAL-1-Abs in patients with hepatocellular carcinoma (16.7%) and lung cancer (13.8%) were significantly higher compared with the other groups: Esophageal cancer (11.6%), colorectal cancer (11.5%), prostate cancer (7.3%), gastric cancer (6.9%), breast cancer (6.9%) and healthy controls (4.2%). Although the positive rates of s-GAL-1-Abs in different cancer types were relatively low, s-GAL-1-Abs may be useful for patients with hepatocellular carcinoma and lung cancer.

show abstract

“…Unlike other conventional tumor markers that detect tumor cell-derived proteins, Ap53Ab has been considered as an innovative tumor marker, in the sense that it detects serum antibodies that emerge in response to tumor cell-derived proteins ( 4 ). Ap53Ab triggers an antigen-antibody reaction, which is positive even in the early stages of cancer, and can detect micro-residual tumor cells after treatment ( 5 , 6 ). As a result of the remarkable results of a study by Shimada et al ( 7 ), the measurement of Ap53Ab levels has been covered from 2007 onwards by medical insurance in Japan for esophageal, colorectal and breast cancer, and can be applied to daily clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Re‑evaluating the clinical significance of serum p53 antibody levels in patients with oral cancer in Japanese clinical practice

et al. 2021

View full text Add to dashboard Cite

TP53 gene mutations can lead to mutant p53 protein accumulation in cancer cells, thereby inducing the production of serum antip53 antibodies (Ap53Ab) in patients with various types of cancer. The aim of the present study was to re-evaluate the clinicopathological and prognostic significance of Ap53Ab using the Ap53Ab ELISA kit, approved by the Japanese Health Insurance System in 2007. Ap53Ab was measured as a tumor marker in 94 patients with oral squamous cell carcinoma (OSCC), by subjecting paraffin-embedded sections obtained from biopsy specimens to immunohistochemical analysis to confirm p53 expression. The associations among Ap53Ab status, p53 expression and clinical significance in OSCC were examined. A total of 23% of the patients were Ap53Ab-positive. Ap53Ab status was found to be significantly associated with p53 expression status in primary tumors (P=0.027), clinical T-category, pathological N-category and pathological stage (P=0.04, P=0.010 and P=0.013, respectively). Kaplan-Meier curve analysis revealed that Ap53Ab status was significantly associated with poor disease-free survival (DFS; P=0.043), and Cox regression analysis revealed that Ap53Ab status was a significant prognostic factor for DFS in patients with OSCC (hazard ratio=2.807; 95% confidence interval: 1.029-7.160; P=0.044). These results suggested that Ap53Ab measurement may reflect the p53 mutation status and an aggressive malignant phenotype, and it may serve as a useful predictive marker candidate for OSCC in clinical practice.

show abstract

Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA

Cited by 28 publications

References 14 publications

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Prevalence of serum galectin‑1 autoantibodies in seven types of cancer: A potential biomarker

Re‑evaluating the clinical significance of serum p53 antibody levels in patients with oral cancer in Japanese clinical practice

Contact Info

Product

Resources

About